Recently published research from Global Markets Direct, "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014", is now available at Fast Market Research
Boston, MA -- (SBWIRE) -- 05/21/2014 -- Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014', provides an overview of the Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
View Full Report Details and Table of Contents
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Companies Mentioned in this Report: Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Amgen Inc., Sanofi, Eli Lilly and Company, Viralytics Ltd., Genentech, Inc., MedImmune, LLC, Gilead Sciences, Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Lentigen Corporation, Amorfix Life Sciences Ltd., Piramal Enterprises Limited, Celltrion, Inc., Astellas Pharma Inc., BioMarin Pharmaceutical Inc., Richter Gedeon Nyrt., Astex Pharmaceuticals, Inc., Genmab A/S, Cyclacel Pharmaceuticals Inc., Celgene Corporation, Onyx Pharmaceuticals, Inc., Bayer AG, Incyte Corporation, Merck KGaA, 4SC AG, Celldex Therapeutics, Inc., Immunomedics, Inc., TG Therapeutics, Inc., Portola Pharmaceuticals, Inc., Mundipharma International Limited, Senesco Technologies, Inc., Panacea Biotec Limited, Simcere Pharmaceutical Group, Hybrigenics S.A., Spectrum Pharmaceuticals, Inc., Memgen, LLC., Hutchison MediPharma Limited, Altor BioScience Corporation, Arno Therapeutics, Inc., Grupo Ferrer Internacional, S.A., Onconova Therapeutics, Inc., Angstrom Pharmaceuticals, Inc., Tragara Pharmaceuticals, Inc., Aprea AB, Biothera, Inc., LFB Biotechnologies, S.A.S, KAEL-GemVax Co., Ltd., Biosidus S.A., Fountain Biopharma Inc., Igenica, Inc., Aprogen, Inc., Karyopharm Therapeutics, Inc., Vivia Biotech, S.L., Lead Discovery Center GmbH, Kancera AB, Conkwest, Inc., International Biotechnology Center Generium, MENTRIK Biotech, LLC, Rhizen Pharmaceuticals SA, bioXPRESS Therapeutics SA, Tolero Pharmaceuticals, Inc., Innovent Biologics, Inc., AbbVie Inc., Epirus Biopharmaceuticals, Inc., Amgen Astellas BioPharma K.K., Senhwa Biosciences, Pharmapraxis
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
- Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014
- Refractory Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2014
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014
- Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
- B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013